首页> 外文期刊>Microbiology and Immunology >Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A
【24h】

Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A

机译:磷脂酰肌醇4-激酶III beta是氧草酸和pachypodol(Ro 09-0179)的抗脊髓灰质炎病毒活性的靶标,位于布雷菲德菌素A靶标步骤的上游

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, phosphatidylinositol 4-kinase III beta (PI4KB) has emerged as a conserved target of anti-picornavirus compounds. In the present study, PI4KB was identified as the direct target of the plant-derived anti-picornavirus compounds, oxoglaucine and pachypodol (also known as Ro 09-0179). PI4KB was also identified as the target via which pachypodol interferes with brefeldin A (BFA)-induced Golgi disassembly in non-infected cells. Oxysterol-binding protein (OSBP) inhibitor also has interfering activity against BFA. It seems that this interference is not essential for the anti-poliovirus (PV) activities of BFA and PI4KB/OSBP inhibitors. BFA inhibited early to late phase PV replication (0 to 6hr postinfection) as well as PI4KB inhibitor, but with some delay compared to guanidine hydrochloride treatment. In contrast with PI4KB/OSBP inhibitors, BFA inhibited viral nascent RNA synthesis, suggesting that BFA targets some step of viral RNA synthesis located downstream of the PI4KB/OSBP pathway in PV replication. Our results suggest that PI4KB is a major target of anti-picornavirus compounds identified in vitro for their anti-picornavirus activities and for some uncharacterized biological phenomena caused by these compounds, and that BFA and PI4KB/OSBP inhibitors synergistically repress PV replication by targeting distinct steps in viral RNA replication.
机译:近年来,磷脂酰肌醇4-激酶III beta(PI4KB)已经成为抗微小RNA病毒化合物的保守靶标。在本研究中,PI4KB被确定为植物来源的抗小核糖核酸病毒化合物,氧格劳辛和厚朴多酚(也称为Ro 09-0179)的直接靶标。 PI4KB还被确定为靶点,通过该靶点厚朴多酚干扰布雷顿德菌素A(BFA)诱导的非感染细胞中的高尔基体分解。氧固醇结合蛋白(OSBP)抑制剂对BFA也具有干扰活性。似乎这种干扰对于BFA和PI4KB / OSBP抑制剂的抗脊髓灰质炎病毒(PV)活性不是必需的。 BFA抑制早期至晚期PV复制(感染后0至6小时)以及PI4KB抑制剂,但与盐酸胍治疗相比有一定的延迟。与PI4KB / OSBP抑制剂相反,BFA抑制了病毒新生RNA的合成,这表明BFA靶向PV复制中PI4KB / OSBP途径下游的病毒RNA合成的某些步骤。我们的结果表明,PI4KB是在体外鉴定出的抗细小核糖核酸病毒化合物的主要靶点,因为它们具有抗细小核糖核酸病毒活性以及由这些化合物引起的某些未表征的生物学现象,并且BFA和PI4KB / OSBP抑制剂可通过靶向不同的步骤协同抑制PV复制在病毒RNA复制中。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号